The latest biotech industry insights, including a publication demonstrating dramatic lifespan extension in aging mouse models.

Genome editing-based therapies typically aim to treat disease by correcting underlying genetic mutations in patient's cells.

Cas9, Transcription Activator-Like Effector Nucleases (TALENs), and Zinc-Finger nucleases (ZFNs) have demonstrated great utility, primarily for genetic knock-out applications, none have been adopted ...

Funding will expand the range of Dualase(R) genome editors for new high morbidity and mortality genetic disease targets. TORONTO, March 18, 2026 /PRNewswire/ - Specific Biologics Inc. ("Specific"), a ...

Researchers at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) have developed a ...

Genome editing-based therapies typically aim to treat disease by correcting underlying genetic mutations in patient’s cells. However, most genetic disorders are caused by dozens or even thousands of ...

Pakistan and China would undertake joint research in advanced agricultural technologies including genomics, genome editing and speed breeding to improve crop productivity, Director General ...

The aim of the pathway is to remove red tape for bespoke therapies designed for patients with rare diseases.

On the Future of Species: Authoring Life by Means of Artificial Biological Intelligence Adrian Woolfson Bloomsbury (2026) Biology is undergoing a transformation. After centuries of studying life as it ...

The U.S. Food and Drug Administration approved the first cell-based gene therapies for sickle cell disease, including the ...

A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way ...